^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ALK negative

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
7d
Trial completion
|
ALK negative
|
lenalidomide • romidepsin
8d
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns. (PubMed, Haematologica)
These findings show improved outcomes in early stage nodal T-cell lymphomas compared to historical data for allcomers. In addition, favorable outcomes in stage I disease treated with chemoradiation support such strategy as an excellent treatment option in this setting.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK negative
8d
Breast Implant-Associated Anaplastic Large Cell Lymphoma Following Prophylactic Mastectomy & Breast Reconstruction: A Case Report. (PubMed, Acta Chir Belg)
Current evidence suggests a possible oncogenic interaction between hereditary susceptibility and chronic implant-associated inflammation. Clinicians must maintain vigilance for BIA-ALCL even in prophylactic settings, as early diagnosis and complete surgical excision remain key to favorable outcomes.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
9d
Inflammatory Myofibroblastic Tumor of the Hard Palate and Gingivobuccal Sulcus Mimicking a Malignant Neoplasm: A Case Report. (PubMed, Cureus)
This case illustrates the compounding diagnostic pitfalls of oral IMT: dual-site involvement, two failed biopsies, ALK negativity in an elderly patient, and focal cytokeratin positivity risking misclassification as spindle cell carcinoma. Awareness of IMT histologic subtypes, meticulous tissue sampling, and systematic immunohistochemical profiling are essential to avoid misdiagnosis and unnecessary aggressive oncologic treatment.
Journal
|
ALK (Anaplastic lymphoma kinase) • CD34 (CD34 molecule) • VIM (Vimentin)
|
ALK negative
14d
Clinicopathologic features of systemic ALK-negative anaplastic large cell lymphoma with TP53 deletion. (PubMed, Am J Clin Pathol)
TP53-D is common in systemic ALK-negative ALCL and is associated with leukemic disease and p53 overexpression. TP53-D did not directly affect survival, but it negated the favorable impact of low IPI and DUSP22-R on PFS, suggesting its potential value as an adverse prognostic marker.
Journal
|
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22)
|
TP53 deletion • ALK negative
15d
New trial
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin)
21d
Angiocentric Variant of Primary Cutaneous CD30-Positive Anaplastic Large Cell Lymphoma: A Case Report and Literature Review. (PubMed, Cureus)
The patient responded favorably to electron beam radiotherapy. This case underscores the importance of early biopsy in atypical or treatment-refractory ulcers and highlights the diagnostic relevance of recognizing rare variants such as the angiocentric subtype.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • ALK negative
21d
Oral manifestations of anaplastic large cell lymphoma: clinicopathological features and main immunophenotypic findings of 3 cases. (PubMed, J Hematop)
One patient was known to decease despite chemotherapy. In conclusion, oral manifestations of ALCL are very rare and more commonly represent a disseminated disease.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression • ALK negative
24d
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (clinicaltrials.gov)
P1/2, N=13, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027
Trial completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
|
Keytruda (pembrolizumab) • Folotyn (pralatrexate)
28d
Primary Anaplastic Lymphoma Kinase-Negative Breast Anaplastic Large Cell Lymphoma Without Breast Implant Association: A Case Report. (PubMed, Int J Surg Pathol)
Given the nonspecific clinical and radiological findings, anaplastic large cell lymphoma should be considered in the differential diagnosis of breast masses, particularly those associated with cystic changes or chronic inflammatory processes. Definitive diagnosis requires thorough histopathological and immunophenotypic evaluation.
Journal
|
ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • ALK negative
30d
New P1 trial
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
|
azacitidine • Epidaza (chidamide)
1m
Deep learning-based CT radiomics for ALK rearrangement status prediction in lung adenocarcinoma. (PubMed, BMC Cancer)
Our CT-based deep learning radiomics model holds promise for non-invasive detection of ALK rearrangements in lung adenocarcinoma, yet remains investigational and necessitates prospective multicenter validation before clinical implementation.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK rearrangement • RET rearrangement • ALK negative